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Abstract
Background: SERPINE2, also known as protease nexin-1, belongs to the serine protease inhibitor (SERPIN)
superfamily. It is one of the potent SERPINs that modulates the activity of plasminogen activators (PAs). PAs and
their SERPIN inhibitors, such as SERPINB2 and SERPINE1, were expressed in the human endometrium and were
implicated in implantation. However, expression data about SERPINE2 in the human endometrium is still unknown.
Thus, we conducted an investigation to reveal the spatiotemporal and cellular expression of SERPINE2 in the
human uterus during the menstrual cycle.
Methods: Seven patients who underwent a hysterectomy and samples of 120 archived patients’ endometrial
curettage or parts of the uterus that were formalin-fixed and embedded in paraffin. Western blotting was
performed to evaluate the specificity and sensitivity of the antibody. Immunohistochemistry was conducted to
localize the SERPINE2 expression site. Quantitative analysis was conducted to evaluate expression levels of SERPINE2
in various sub-phases of the menstrual cycle.
Results: The SERPINE2 protein was primarily detected in the uterine fluid during the mid- and late-secretory
phases of the menstrual cycle. It was predominantly expressed in the luminal and glandular epithelium, less in the
myometrium, and only dispersedly in certain stromal cells throughout the menstrual cycle. A quantitative analysis
of expression levels of SERPINE2 in the glandular epithelium revealed that it was highly expressed in the
endometrium during the secretory phase compared to the proliferative phase.
Conclusions: The SERPINE2 protein is highly expressed in the endometrium during the secretory phase, indicating
that it may participate in tissue remodeling involved in implantation.
Background
The plasminogen activator (PA) system refers to the PA
and its cognate inhibitors [1]. The system includes two
forms of PA, tissue-type (PLAT or tPA) and urokinase-
type (PLAU or uPA), and four forms of serine protease
inhibitors (SERPIN), including SERPINA5 (also called
protein C inhibitor, PCI), SERPINB2 (also called plasmi-
nogen activator inhibitor 2, PAI-2), SERPINE1 (also
called plasminogen activator inhibitor 1, PAI-1), and
SERPINE2 (also called protease nexin-1, PN-1) [2].
The PA system is associated with many reproductive
processes, including ovulation, embryogenesis, and
embryo implantation in female reproductive tissues
[1,3]. How SERPIN modulates the proteolytic activities
of PLAT/PLAU in reproductive tissue remodeling is of
great importance.
Tissue remodeling requires a fine-tuned balance
between levels of proteases and their cognate inhibitors.
The PA is involved in tissue remodeling by converting
abundant extracellular plasminogen into plasmin, an
active protease, which degrades the extracellular matrix.
The classical substrate of plasmin is fibrin, but in fact,
many other matrix proteins can be cleaved by this
enzyme [1].
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detected in the human uterus, including the uterine
fluid [4-6], and the endometrium during cycling [5-9]
and implantation [10]. SERPINB2 [8] and SERPINE1
[7,8] were demonstrated to be present in the human
endometrium. SERPINE1 was even detected in human
and mouse uteri during implantation [10,11], indicating
that the PA inhibitor is involved in implantation.
SERPINE2 has broad anti-protease activity specific to
serine proteases, including trypsin, thrombin, plasmin,
PLAU [12], and prostasin [13]. It is widely expressed in
various tissues [14]. In the uterus, it is reported that
expression levels of SERPINE2 in the monkey endome-
trium and placenta during early pregnancy were weak or
below the level of detection [15]. In rats, Serpine2 mes-
senger (m)RNA was exclusively detected in endometrial
stromal cells of the uterus, in particular on day 6.5 post-
coitally, thus suggesting that it may be involved in the
implantation process [16].
Recently, SERPINE2 protein was reported to be
expressed in the murine uterus during the estrous cycle,
pregnancy, and lactation [17]. It is predominantly
expressed in the luminal and glandular epithelium and
weakly in stromal cells and myometrium. It seems that
different species have different expression patterns for
the SERPINE2 protein. So far, there is no study on this
aspect in the human uterus. Herein, we conducted an
investigation to reveal the spatiotemporal and cellular
expression of SERPINE2 in the human uterus during
the menstrual cycle.
Methods
Sample collection
Uterine fluid aspirates were collected under the consent
of patients (n = 7) who were to undergo a hysterectomy
because of a leiomyoma or adenomyosis. After anesthe-
sia and before surgery, uterine fluid in the cavity was
directly aspirated using an embryo transfer catheter
(Labotect, Goettingen, Germany). Then, the cavity was
flushed using 3 mL of saline. The two solutions were
mixed for analysis. On day 1 of the operation, blood
was aspirated to examine the serum concentration of
estradiol and progesterone to evaluate the phase of the
menstrual cycle. A sample from endometrial curettage
was also formalin-fixed and paraffin-embedded (FFPE)
for a histological evaluation. Menstrual cycle can be
dated into 6 sub-phases according to the anatomical
changes within the endometrial biopsy including, early
proliferative (EP) (days 5-7), mid-proliferative (MP)
(days 8-10), late proliferative (LP) (days 11-14), early
secretory (LS) (days 14-21), mid-secretory (MS) (days
22-24), and late secretory (LS) (days 25-28) phases [18].
Informed consent for all samples was obtained from all
patients.
To analyze the SERPINE2 protein expression in differ-
ent phases of the menstrual cycle, 120 archived FFPE
samples of endometrial curettage or parts of the uterus
from patients of reproductive age at various sub-phases
of the menstrual cycle judged by a pathologist were
obtained from the Department of Pathology, Mackay
Memorial Hospital (Taipei, Taiwan). Wax blocks, 25
cases of EP, 20 cases of MP, 14 cases of LP, 20 cases of
ES, 21 cases of MS, and 20 cases of LS, were prepared
from patients who were to undergo a hysterectomy
because of a leiomyoma or adenomyosis. All retrieved
wax blocks had been treated at the hospital for 2 years.
The Institutional Review Board approved this study
(reference number: MMH-I-S-441).
Western blotting
To assess the specificity of the antibody, 400 ng of
recombinant glutathione S-transferase (GST)-human
SERPINE2 protein (Abnova, Taipei, Taiwan) was
resolved by sodium dodecylsulfate polyacrylamide
gel electrophoresis (SDS-PAGE) on a 10% gel slab (8.2 ×
7.3 × 0.075 cm) and was transferred to a nitrocellulose
membrane for immunostaining according to a previously
d e s c r i b e dm e t h o d[ 1 9 ] .M e mbranes were blocked with
10% (w/v) skim milk in phosphate-buffered saline (PBS)
(blocking solution) for 2 h, and then incubated with our
homemade anti-mouse SERPINE2 antiserum (1: 5000)
[17,20], anti-human SERPINE2 antibody (1: 1000, catalog
n o .A F 2 9 8 0 ,R & DS y s t e m s ,M i n n e a p o l i s ,M N ,U S A ) ,o r
another anti-human SERPINE2 antibody (1: 1000, pro-
duct no. H00005270-B01, Abnova) in blocking solution
for 2 h at 37°C. After gentle agitation in four changes of
PBS for 15 min each, membranes were immunoreacted
with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit immunoglobulin G (IgG) (1: 5000, GE Healthcare
Life Sciences, Piscataway, NJ, USA), donkey anti-goat
IgG (1: 3000, Jackson ImmunoResearch, West Grove, PA,
USA), or horse anti-mouse IgG (1:3000, Cell Signaling
Technology, Beverly, MA, USA), respectively, in blocking
solution for 2 h at 37°C. After gentle agitation as men-
tioned above, immunoreactive bands were revealed using
an enhanced chemiluminescent substrate according to
the manufacturer’s instructions (Western Lightning;
PerkinElmer, Boston, MA, USA).
To evaluate the sensitivity of the antibody, 100 μgo fa
tissue extract from endometrial curetting was resolved,
transferred onto a blot, and detected using anti-mouse
SERPINE2 antiserum (1: 5000) or an anti-human SER-
PINE2 antibody (1: 1000) following the method
described above.
To examine the expression of SERPINE2 in the uter-
ine fluid, 50 μg of uterine luminal proteins was applied
and detected using anti-mouse SERPINE2 antiserum
(1: 3000) following the same method.
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Immunohistochemical analysis was performed on an
automatic staining machine (BenchMark XT, Ventana
Medical Systems, Tucson, AZ, USA) using the iVIEW 3,
3-diaminobenzidine (DAB) detection kit (Ventana Medi-
cal Systems). After tissue sections (4 μm) on slides were
deparaffinized and hydrated, they were heated to 95°C for
8 min and then 100°C for 4 min to induce antigen retrie-
val using Ventana Cell Conditioner 1 (Ventana Medical
Systems). After cooling to room temperature for 30 min,
the slides were treated with an iVIEW inhibitor at 37°C
for 4 min to inactivate the endogenous peroxidase
activity. Slides were then incubated with anti-SERPINE2
antiserum or antiserum pretreated with SERPINE2 anti-
gen-conjugated beads diluted 1: 1000 in blocking solution
at 37°C for 16 min. After rinsing with PBS, slides were
treated with iVIEW biotin-conjugated IgG in blocking
solution for 8 min at room temperature. Slides were
rinsed again and then incubated with iVIEW streptavi-
din-conjugated HRP in blocking solution for 8 min at
room temperature. Protein signals were developed by
iVIEW DAB and hydrogen peroxide for 8 min at 37°C.
Slides were finally incubated with iVIEW copper for
4 min to enhance the signal intensity, counterstained
with hematoxylin (Vector Laboratories, Burlingame, CA),
and photographed with a Nikon Eclipse E600 microscope
(Tokyo, Japan) or Zeiss AxioImager Z1 microscope sys-
tem (Wetzlar, Germany) equipped with a CCD camera
and an automated acquisition system (TissueGnostics,
Vienna, Austria). Pictures were acquired using Tissue-
Faxs software (TissueGnostics). The percentage of posi-
tively stained cells was determined using HistoQuest
software (TissueGnostics). Five endometrial glands on a
slide for each individual patient at a given sub-phase of
t h em e n s t r u a lc y c l ew e r ec h o s e nt oe v a l u a t et h el e v e lo f
staining according to the mean intensity of DAB, refers
to the staining signal of SERPINE2, of the stained cells
which were counterstained with hematoxylin. The strong
intensity was suggested that more than 50% of glandular
epithelial cells had a staining intensity of > 15. The weak
intensity was suggested that more than 60% of glandular
epithelial cells had a staining signal of < 10. The staining
signal other than the two cases was referred to the med-
ium signal. A chi-square test was performed to compare
the significance of difference in expression levels of SER-
PINE2 among patients at different sub-phases of men-
strual cycle.
Results
To assess the specificity of the antibodies, we analyzed
two commercially available anti-human SERPINE2 anti-
bodies and homemade anti-mouse SERPINE2 antiserum
by Western blotting. As shown in Figure 1, all antibo-
dies could recognize the recombinant GST-human
SERPINE2 protein (Figure 1A), indicating that our anti-
body has specificity for the human SERPINE2 protein.
To evaluate the sensitivity of the antibody, a tissue
extract from endometrial curettage was resolved on a
gel and Western-blotted using the three antibodies. An
apparent 44-kDa protein band corresponding to human
SERPINE2 was immunodetected by our anti-mouse
SERPINE2 antibody, while many non-specific crossed-
reacted protein bands were blotted by the commercial
antibodies. In addition, an approximately 75-kDa protein
band corresponding to the complex of SERPINE2 and a
certain protease demonstrated in previous studies
[14,17,21,22] was found. Thus, the sensitivity of our
antibody apparently excelled those of the commercial
antibodies (Figure 1B). These data indicated that our
antibody has high specificity and sensitivity for detecting
the human SERPINE2 protein.
Using the antibody, SERPINE2 was detected in the
endometrial fluid of the human uterus (Figure 1C). It
was obvious that there was more SERPINE2 in the
secretory phase (lanes 2 and 6) than in the proliferative
phase (lanes 1, 3, 4, and 7). Thus, SERPINE2 is indeed a
human uterine secretory protein.
An immunolocalization study was conducted to reveal
the cellular localization of the SERPINE2 protein in the
early secretory phase uterus. As shown in Figure 2, SER-
PINE2 was primarily detected on the apical surface of
the luminal epithelium (Figure 2A) and glandular
epithelium (Figure 2B), but weakly on the myometrium
(Figure 2C). In contrast, the protein signal in stromal
cells was dispersedly distributed on some unidentified
cells, parts of which may be macrophage as judged by
cell morphology (Figure 2B). In addition, SERPINE2 was
detected on endothelial cells of the vessel (Figure 2C) as
demonstrated by a previous study [23]. When slides
were immunostained with control antiserum, no signal
was detected (data not shown).
To further evaluate the expression of the SERPINE2
protein in various sub-phases of the menstrual cycle, we
examined endometrial slides prepared from early-, mid-,
and late-proliferative as well as secretory phases by
immunohistochemistry. The results showed that the sig-
nal was relatively weaker during the proliferative phase
(Figure 3A-C), while it was strongly detected in the
glandular epithelium during the secretory phase (Figure
3D-F), especially in the mid- and late-secretory phase
(Figure 3E, F).
Positively stained cells in the endometrial gland were
quantified to analyze expression levels of the SERPINE2
protein. The signal intensity was determined by quanti-
tative software. Scattergrams of the staining intensity
(Figure 4B) indicated strongly and weakly stained cells
in the glandular epithelium (Figure 4A). The results
implied that weakly stained cells in the gland were
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strongly stained cells were predominantly from the
secretory phase (Figure 4C). Thus, SERPINE2 was pri-
marily expressed in secretory-phase endometrial glandu-
lar cells from which it was secreted into the lumen of
the uterus.
Discussion
In this study, we demonstrated that the SERPINE2 pro-
tein, an inhibitor of PAs, is highly expressed in the
human uterus during the secretory phase. However, its
levels are low in the uterus during the proliferative
phase. It is primarily expressed in the luminal and
glandular epithelium, weakly expressed in the myome-
trium, and dispersedly expressed by certain stromal
cells.
Proteases are known to be involved in extracellular
matrix degradation required for implantation, including
cysteine, serine, and matrix metalloproteinases [24]. PA
serine proteases and their cognate inhibitors are
involved in implantation [1,3]. Tissue remodeling is an
important biological event for many reproductive pro-
cesses that occur in the ovary, uterus, and placenta,
such as follicle growth, ovulation, the estrous cycle,
implantation, and placentation [1,3]. SERPINE2 was pre-
viously demonstrated to primarily be upregulated in
dominant follicles during follicle growth in cattle [25,26]
and during ovulation in mice [27]. It is also highly
expressed in the rodent uterus during implantation and
pregnancy [17].
Similar to the rodent data, in this study, we revealed
that the SERPINE2 protein was highly expressed in the
glandular epithelium of human uterus around the time
of the implantation window. These data suggest a role
for SERPINE2 in regulating tissue remodeling during
implantation.
Human SERPINE2 has high amino-acid identities
with the rat and mouse SERPINE2, at 100% and 89%,
respectively. Anti-mouse SERPINE2 antiserum can
cross-react with rat SERPINE2 in the uterus [17], indi-
cating that it would cross-react with human SER-
PINE2. In this study, we demonstrated that anti-mouse
SERPINE2 antiserum recognized the human SERPINE2
protein. Interestingly, we found that only one SER-
PINE2 protein form existed in the human uterus,
while two isoforms were found in the mouse and rat
uterus [17].
Our anti-SERPINE2 antibody, produced using a highly
purified protein as the immunogen [17], was very sensi-
tive at detecting tissues in which there was trace expres-
sion of SERPINE2 [17,20], even better than the
commercial antibodies. In this study, the commercial
antibodies could not specifically detect SERPINE2’s
expression in endometrial tissues, demonstrating the
sensitivity of our antibody. Weak or very low levels of
SERPINE2 in the monkey endometrium and placenta in
a previous study may have resulted from the fact that
they used the peptide or Escherichia coli-expressed pro-
tein as the immunogen which is often not in the native
conformation of the protein [15].
Figure 1 Antibody specificity and presence of the SERPINE2 protein in human uterine fluid. (A) Four hundred nanograms of recombinant
human SERPINE2 was resolved on 10% SDS-PAGE and followed by Western blotting using anti-mouse SERPINE2 antiserum (lane 1), an anti-
human SERPINE2 antibody (R&D) (lane2), or another anti-human SERPINE2 antibody (Abnova) (lane 3). (B) One hundred micrograms of the
extract of endometrial curettage was analyzed by anti-mouse SERPINE2 antiserum (lanes 1 and 2) and an anti-human SERPINE2 antibody (R&D)
(lanes 3 and 4). (C) Fifty micrograms of uterine fluid proteins collected from each individual patient (n = 7) was Western-blotted using anti-
mouse SERPINE2 antiserum (1:3000) (upper panel). EP, MP, and LP indicate early-, mid-, and late-proliferative phases, and ES and MS indicate
early- and mid-secretory phases, respectively. The blot was also overexposed to clearly display the staining signal (lower panel).
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a complex of approximately 75 kDa with PLAU [14,21,22]
or about 82 kDa with prostasin [13]. A 75-kDa protein
complex was found in the protein extract of murine and
rat uteri [17]. Similarly, the complex was also detected in a
human endometrial tissue extract (Figure 1B), indicating
that SERPINE2 may act in the human uterus with a cer-
tain protease that may be involved in tissue remodeling.
Prostasin is highly expressed, but its inhibitor, SER-
PINE2, is barely expressed in the glandular epithelium
Figure 2 Localization of SERPINE2 in the human uterus. Longitudinal sections of the early secretory phase uterus (n = 5) on the slide were
incubated with anti-mouse SERPINE2 antiserum and then treated with biotin-conjugated goat-anti-rabbit IgG and HRP-conjugated streptavidin
(brown). For contrast, specimens were further stained with hematoxylin (blue). The representative picture is shown. Magnified pictures of the
luminal epithelium (A), glandular epithelium (B), and myometrium (C) are shown. Bar = 50 μm. bv, blood vessel; ge, glandular epithelium; le,
luminal epithelium; m, muscle; s, stroma.
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[ 1 5 ] .H o w e v e r ,t h eS E R P I N E 2p r o t e i ni sh i g h l y
expressed in the human endometrium, although prosta-
sin protein expression in the human uterus is still
unknown. Whether SERPINE2 regulates the proteolytic
activity of prostasin in the human uterus awaits further
investigation.
PLAT, PLAU, SERPINE1, and SERPINB2 were found
to be expressed in the human endometrium [5-10].
PLAU mRNA is expressed by stromal cells in all phases
of the menstrual cycle. However, the PLAU protein is
expressed by epithelial and stromal cells in the early-
proliferative and late-secretory phases but is nearly
undetectable in the mid-secretory phase of the men-
strual cycle [7]. SERPINE1 mRNA and protein were
reported to predominantly be expressed by stromal cells
in the late secretory phase [7]. The SERPINB2 protein
was found at very low concentrations and was expressed
by certain stromal cells in the human endometrium.
Expression levels of this protein showed no difference
between the proliferative and secretory phases [8]. Our
preliminary results in analyzing the relative mRNA
expression levels of PA inhibitors showed that SER-
PINE2 mRNA was the most highly expressed PA inhibi-
tor in the extract of the human uterus (unpublished
observations). Thus, the SERPINE2 protein may be the
major PA inhibitor in the human uterus. This was also
found in the mouse uterus [17].
While SERPINE2 was expressed in the mouse and rat
uteri [17], it was below the level of detection in the
monkey uterus [15]. This is the first report to demon-
strate that SERPINE2 is prominently expressed by the
Figure 3 Glandular epithelial expression of the SERPINE2 protein in the endometrium during the menstrual cycle. Sections prepared
from endometrial curettage during early-proliferative (EP), mid-proliferative (MP), late-proliferative (LP), early-secretory (ES), mid-secretory (MS),
and late-secretory (LS) phases were incubated with anti-mouse SERPINE2 antiserum and then treated as described in Figure 2. Bar = 50 μm. bv,
blood vessel; ge, glandular epithelium; s, stroma.
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cell acquisition and quantification software (A). The expression signal of a respective glandular gland was quantified using HistoQuest software
and is presented as a scattergram. Each spot on the scattergram stands for the intensity of one cell (B). The relative SERPINE2 protein expression
levels in patients’ glandular glands at various sub-phases of the menstrual cycle are shown as bar diagrams (C). Differences are significant among
patients at various groups (c = 69.32, p < 0.0001).
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protein is present in the uterine fluid. PA activity was
also demonstrated to be present in the uterine fluid
[4-6]. Thus, the SERPINE2 protein may exert an inhibi-
tory role of modulating PA activity in the uterine milieu.
In conclusion, cellular localization of the SERPINE2
protein in the human uterus suggests that it may play
important roles in PA-modulated tissue remodeling.
The high expression of the SERPINE2 protein in the
secretory phase suggests that it might be associated with
embryo implantation.
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